

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 20, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Peyman

Serial No.:

10/667,161

Filed:

September 19, 2003

Group Art Unit: Confirmation No.:

1615 8452

Examiner:

Sheikh

Title:

OCULAR SOLUTIONS

Attorney Ref.:

PMAN-25

Cincinnati, Ohio 45202

January 20, 2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56 and means of complying therewith according to 37 C.F.R. §§1.97 and
1.98, the references listed on the attached form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. Applicant has the following co-pending applications disclosing use of one or more macrolides: 10/289,772, 10/631,143, and 10/752,124. The references submitted in this IDS are or were submitted or cited in applicant's co-pending applications, and are included in the pending application to ensure compliance with applicant's duty of disclosure under 37 C.F.R. §1.97.

The Examiner is urged to consider the cited references listed on the attached form PTO-1449, and to make an independent decision with respect to materiality.

In accordance with 37 C.F.R. §1.97(c), attached is a check in the amount of \$180.00 as set forth in 37 C.F.R. §1.17(p). If any additional fee is required to complete this communication, please charge Deposit Account No. 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

Beverly A. Lyman, Ph.D.

Reg. No. 41,961

2700 Carew Tower 441 Vine Street Cincinnati, OH 45202 513 241-2324 513 421-7269 (facsimile)

The PTO did not receive the following listed Item(s) the Check.

ORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. PMAN/25

SERIAL NO. 10/667,161

APPLICANT Gholam Peyman

FILING DATE September 19, 2003 **GROUP** 1615

THAT IS NOT THE PARTY OF THE PA									U.S. F	PATENT DOCUMENTS			
EXAMINER - INITIAL			PA	TEN	4 TI	IUM	BEF	₹	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A	4	0	7	9	0	3	8	03/14/78	Choi et al	260	47	03/05/76
-	A.B	4	0	9	3	7	0	9	06/06/78	Choi et al	424	19	01/28/75
	A.C	4	1	3	1	6	4	8	12/26/78	Choi et al	424	22	03/02/78
	A.D	4	1	3	8	3	4	4	02/06/79	Choi et al	252	1	08/24/77
	A.E	4	1	8	0	6	4	6	12/25/79	Choi et al	528	153	03/03/78
	A.F	4	3	0	4	7	6	7	12/08/81	Heller et al	424	78	05/15/80
	A.G	4	9	4	6	9	3	1	08/07/90	Heller et al	528	320	06/14/89
	A.H	5	4	2	9	4	6	0	03/15/94	Nussenblatt et al	514	11	12/20/89
	A.I	5	3	8	7	5	8	9	02/07/95	Kulkarni	514	291	11/17/92
	A.J	5	4	1	1	9	6	2	05/1995	Kaswan			
J	A.K	5	4	5	7	1	8	2	10/10/95	Wiederrecht et al	530	402	02/15/94
					FC	RE	IGN	PAT	ENTS OR PU	BLISHED FOREIGN PATENT A	APPLICATION	NS	
					MEI BEF			Р	UBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L	wc	00	/66	122			11/	09/00	PCT	A61K	31/436	N/A

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
A.L	WO 00/66122	11/09/00	PCT	A61K	31/436	N/A
A.M	WO 02/085928	10/31/02	PCT	C07K	7/54	Abstract only
A.N	WO 2004/014373	02/19/04	PCT	A61K	31/436	N/A
A.O	EP 1074255	02/07/01	EP	A61K	31/40	N/A
A.P	WO 99/34830	07/15/99	PCT	A61K	47/18	N/A
A.Q	AU 17386/88	Unknown	AU		Unknown	N/A

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

`	A.R	Algvere et al, Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD, European J of Ophthalmology (1999), 9(3):217-230
	A.S	Anderson et al., A Role for Local Inflammation in the Formation of Drusen in the Aging Eye, American Journal of Ophthalmology, Vol. 134, No. 3, September 2002, pp. 411-431
	A.T	Apel et al., A subconjunctival degradable implant for cyclsoprine delivery in corneal transplant therapy, Curr. Eye Res. 14:659-667, 1995

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE SERIAL NO. SUBSTITUTE FORM PTO-1449 ATTY, DOCKET NO. PATENT AND TRADEMARK OFFICE PMAN/25 10/667,161 (MODIFIED) APPLICANT INFORMATION DISCLOSURE STATEMENT BY APPLICANT Gholam Peyman **GROUP** FILING DATE (Use several sheets if necessary) September 19, 2003 1615 (37 CFR 1.98(b)) U.S. PATENT DOCUMENTS FILING DATE ISSUE **EXAMINER** IF APPROPRIATE PATENT NUMBER **CLASS SUBCLASS** INITIAL DATE PATENTEE 06/23/98 514 302 07/18/94 5 0 6 0 Honbo et al B.A 06/30/98 424 423 09/27/95 5 7 3 0 9 Ashton et al B.B 1 514 10/08/97 B.C 5 9 5 2 3 7 1 09/14/99 Baker et al 443 12/05/97 424 425 B.D 5 9 6 8 5 4 3 10/19/99 Heller et al 424 278.1 09/23/97 B.E 6 0 0 4 5 6 5 12/21/99 Chiba B.F 6 3 3 3 12/2001 Wong et al 05/30/2001 424 78.04 B.G 6 3 5 0 4 4 2 02/26/02 Garst B.H 6 4 6 2 0 7 10/2002 Castillejos 11/2002 Tuse et al B.I 6 4 8 2 7 9 9 07/22/03 Nelson et al 424 426 08/04/00 B.J 6 5 0 6 2 0 6 03/18/03 13/00 01/31/01 6 5 3 4 6 9 3 Fischell et al. A61F B.K FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS TRANSLATION **PUBLICATION COUNTRY OR** DOCUMENT PATENT OFFICE **CLASS SUBCLASS** (YES/NO) DATE NUMBER Unknown N/A B.L AU 20350/92 Unknown ΑU A61K 9/06 Abstract only 01/30/02 CN B.M CN 1333018 A61K 38/13 Abstract only 03/20/02 CN CN 1340358 B_.N CN A61K 9/00 Abstract only CN 1456350 11/19/03 B.O B.P DE 19810655 09/16/99 DE A61K 38/13 Abstract only 9/08 Abstract only B.Q EP 1142566 10/10/01 EP A61K OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) B.R Aramant et al, Retinal transplantation, Science & Medicines (2000), 7:20-29 Carmo et al, Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotocin-induced diabetes, Mediators of B.S Inflammation (2000), 9(5):243-248 Chiou, Topical Treatment of Ocular Hypertension, Glaucoma, Ischemic Retinopathy and Age-Related Macular Degeneration B.T with Ophthalmic Formulation of Dopamine Antagonists, U.S. Patent Application Publication No. US 203/0069232, published 04/10/03 DATE CONSIDERED **EXAMINER** EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.

Include a copy of this form with next communication to applicant.

SUBSTITUTE (MODIFIED)	FORM F	PTO-	-144	9	-		-			ENT OF COMMERCE FRADEMARK OFFICE	ATTY. PMAN	DOCKET N /25	О.	SERI/ 10/66	AL NO. 7,161
•				-					OSURE LICANT		APPLI Gholar	CANT n Peyman			
(37 CFR 1.98	(b))		(Us	e se	vera	al sh	neet	s if ne	ecessary)			DATE nber 19, 200)3	GROU 1615	JP
									U.S. F	PATENT DOCUMENTS					
EXAMINER INITIAL			PA	TEN	NT N	IUM	BEI	₹	ISSUE DATE	PATENTEE	_	CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	C.A	6	6	1	3	3	5	5	09/02/03	Ng et al		424	462		05/11/01
-	С.В	6	6	1	7	3	4	5	09/09/03	Gregory et al		514	395		09/12/00
	C.C	6	6	6	7	3	7	1	12/23/03	Ng et al		525	462		11/14/02
	C.D	6	6	7	0	3	9	8	12/2003	Edwards et al					
	C.E	6	6	7	3	8	0	7	01/2004	Sakai et al					
	C.F	6	7	1	3	0	8	1	03/2004	Robinson et al		·c.			
C.G															
C.I															
<u>.</u>															
	C.K														
					FC	RE	IGN	PAT	ENTS OR PU	BLISHED FOREIGN PA	TENT A	PPLICATION	NS		
					MEN BEF			P	JBLICATION DATE	COUNTRY OF PATENT OFFICE		CLASS	SUBCL	ASS	TRANSLATION (YES/NO)
	C.L	JP	10-2	2187	787			08/	18/98	JP		A61K	38/22		Yes
	C.M	JP	199	703	096	6		02/0	04/97	JP		A61K	31/365		Yes
	C.N	JP	200	1-06	5419	98		03/	13/01	JP		A61K	38/22		Yes
	C.O	WC	02	/242	234			03/2	28/02	PCT	:	A61K	48/00		N/A
	C.P	wc	03	/051	1385	5		06/:	26/03	PCT		A61K	38/13		Abstract only
	C.Q	wc	03	/017	7990)		03/0	06/03	PCT		A61K	31/00		N/A
					0	THE	ER (ocu	JMENTS (Incl	uding Author, Title, Date	, Place o	f Publication	1)	,	
	C.R								netics of subc /2001), 42(4):	onjunctivally administere 3332	ed cylcos	porine A. Lo	ocal delive	ery prior	to chemotherapy for
	C.S									and GDNF Enhance N gy 164,60-60 (2000)	eurite Bra	anching or E	longation	from De	eveloping Dopamine
	C.T									etal neuroretinal cells in y (1999), 157:58-68	advance	d retinitis pig	mentosa	patients	: Results of a long-
EXAMINER										DATE CONS	IDERED	-			
EXAMINER: Include a copy										nance. Draw line throug	h citation	n only if not i	n conform	ance <u>ar</u>	nd not considered.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE (MODIFIED) PMAN/25 10/667,161 **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Gholam Peyman **GROUP** (Use several sheets if necessary) FILING DATE (37 CFR 1.98(b)) September 19, 2003 1615 U.S. PATENT DOCUMENTS FILING DATE **EXAMINER** ISSUE IF APPROPRIATE INITIAL PATENT NUMBER DATE **PATENTEE CLASS SUBCLASS** D.A D.B D.C D.D D.E D.F D.G D.H D.I D.J D.K FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS DOCUMENT **PUBLICATION** COUNTRY OR TRANSLATION NUMBER DATE PATENT OFFICE **CLASS SUBCLASS** (YES/NO) D.L WO 2004/096261 11/11/04 PCT A61K 38/13 Abstract only D.M WO 2004/043480 05/27/04 **PCT** A61K 38/00 D.N WO 2005/030205 04/07/05 **PCT A61K** 31/436 N/A 02/10/05 **PCT** A61P 27/02 N/A D.O WO 2005/011813 03/09/89 PCT D.P WO 89/01772 A61K 9/00 N/A D.Q WO 99/42104 08/26/99 PCT A61K 31/435 N/A OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) D.R Del Cerro et al, Histologic correlation of human neural retinal transplantation, Invest. Ophthalmology & Visual Science (2000), 41(10):3142-3148 D.S Donnenfeld et al., Cyclosporine provides effective treatment for dry eye, Therapeutic Updates in Ophthalmology, Special Issue, July 1999, pp. 1-3 Enyedi et al, Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and D.T dexamethasone (DEX), Invest. Ophthalmology and Visual Science, Vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994, abstract **EXAMINER** DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.

Include a copy of this form with next communication to applicant.

SUBSTITUTE (MODIFIED)	FORM F	PTO-1	449	•							COMMERC ARK OFFIC		ATTY PMAN		KET N	Э.	SERI/ 10/66	AL NO. 7,161
								LOSUF					APPL Ghola					
(37 CFR 1.98	(b))	(1	Use	sev	era	l she	ets if ı	necessa	ary)				FILIN Septe		ΓΕ 19, 200	3	GRO 1615	JP
			`\						U.S. F	PATENT	DOCUMEN	TS						
EXAMINER INITIAL			PAT	EN.	TN	UMB	ER		SUE ATE		PATENTE	E		С	LASS	SUB	CLASS	FILING DATE IF APPROPRIATE
	E.A														*			
-	E.B																	
	E.C	П									-					:		
	E.D	П																
 	E.E																	
	E.F																	
	E.G																	
	E.H																	
	E.I	П																
	E.J					T												
	E.K																	
-					FO	REIG	N PA	TENTS	OR PU	BLISHED) FOREIGN	PA	TENT A	APPLI	CATION	18		
				CUN				PUBLIC DA	CATION	F	COUNTRY PATENT OF			CL	ASS	SUBC	LASS	TRANSLATION (YES/NO)
	E.L																	
	E.M																	
	E.N																	
	E.O																	
	E.P																	·
	E.Q																	
					0	THEF	R DOC	CUMEN	TS (inclu	uding Au	thor, Title, [Date	, Place	of Pu	blication	1)		
	E.R	Eny Vol.	edi 15,	et a No	I, <u>A</u> r . 5,	n intra pp. 5	vitrea 49-55	al device 7	é providi	n sustain	ned release	of c	yclspor	ine an	d dexar	nethaso	<u>ne</u> , Curr.	Eye Res. May 1996,
	E.S	Gan Mon	weg ats	et a	al, <u>T</u> er f	hera ur Au	py of genh	Goldma eilkunde	nn-Favro e, Vol., 1	e's Vitrec 99, No. 3	o-Retinal De 3, Septembe	gen er 1	eration 991, pp	with (Cyclospo 205	orin A ar	d Bromo	ocriptine, Klinische
	E.T	Gilb	ard,	<u>EV</u>	/ In	tervie	w: Ele	ectrolyte	e balance	e is key t	to dry-eye p	rodu	uct's su	ccess,	EyeWo	orld, Feb	ruary 20	00, pp. 20ff
EXAMINER							-				DATE CO)NS	IDERE	D				
EXAMINER: Include a cop										mance. [Oraw line th	roug	gh citati	on onl	y if not	in confo	mance <u>a</u>	not considered.

SUBSTITUTE (MODIFIED)	FORM F	PTO-	144	9								COMMERCE ARK OFFICE		ATTY.	DOCKE 25	TNC).	SERIA 10/667	
									SURE ICANT					APPLI Gholar	CANT n Peyma	ın			
(37 CFR 1.98	(b))	,	(Use	e se	vera	ıl she	ets i	if ne	cessary)					FILING	DATE	2003	3	GROU 1615	P
					•				U.	.S. PA	TENT	DOCUMENT	s						
EXAMINER INITIAL			PA	TEN	IT N	UME	BER		ISSUE DATE			PATENTEE	:		CLAS	ss	SUBC	LASS	FILING DATE IF APPROPRIATE
	F.A																		
-	F.B																		
	F.C																		
	F.D																		
	F.E	F.F																	
	F.F	E G																	
	F.G																		
	F.H	3																	
	F.I	.н																	
	F.J																		
	F.K																		
-					FO	REI	GN F	PATE	ENTS OR	PUBL	ISHED	FOREIGN P	'Α٦	TENT A	PPLICAT	ΓΙΟΝ	s		
								Pι	JBLICATI DATE	ON		COUNTRY O			CLASS	3	SUBCL	ASS	TRANSLATION (YES/NO)
	F.L																		
	F.M																		
	F.N										<u> </u>								
	F.O											<u></u>							***
	F.P																		
	F.Q																		
					0	THE	R D	ocu	IMENTS ((Includ	ling Aut	hor, Title, Da	te,	, Place o	of Publica	ation))		
	F.R	Gri	sola	no e	et al.	., <u>Re</u>	tinal	Tox	icity Stud	y of In	travitre	al Cydosporii	<u>n,</u> (Opthalm	ic Surge	ry, N	March 198	36, 17:15	55-156
	F.S	Ha: Pul	gem	an e	et al No.	., <u>Dia</u> . US	gno 2002	stics 2/00	and The 15957, pu	rapeut ublishe	tics for ed 02/07	Macular Dege 7/02	ene	eration-l	Related I	Disor	ders, U.S	S. Patent	Application
	F.T	Jia Ro	ng e yal (t al, Colle	Cor ege	rneal of Su	elec	ctrore	etinograpi rats, inves	hic fun st. Oph	nction re	escued by no ology & Visua	rm I S	al retina Science	I pigmer (1994), 3	nt epi 15(13	thelial gr):4300-4	afts in re 308	tinal degenerative
EXAMINER		OTHER DOCUMENTS (Inc. Grisolano et al., Retinal Toxicity Study of Hageman et al., Diagnostics and Therap Publication No. US 2002/0015957, publication and Location Study of Hageman et al., Corneal electroretinographic Royal College of Surgeons rats, Invest.										DATE CON	ISI	DERED					

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. 10/667,161 (MODIFIED) PATENT AND TRADEMARK OFFICE PMAN/25 **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Gholam Peyman **GROUP** (Use several sheets if necessary) **FILING DATE** (37 CFR 1.98(b)) September 19, 2003 1615 U.S. PATENT DOCUMENTS ISSUE FILING DATE **EXAMINER SUBCLASS** IF APPROPRIATE **CLASS** INITIAL PATENT NUMBER DATE PATENTEE G.A G.B G.C G.D G.E G.F G.G G.H G.I G.J G.K FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS **DOCUMENT PUBLICATION COUNTRY OR TRANSLATION** SUBCLASS **NUMBER** PATENT OFFICE CLASS (YES/NO) DATE G.L G.M G.N G.O G.P G.Q OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) G.R Karacorlu et al., Lack of toxicity of intravitreally administered interferon Alpha-2a, Ophthalmic Surger (1999), 23:833-35 G.S Keep et al., Introduction: Immunosuppressants as Neuroprotective Agents" Immunosuppressant Analogs in Neuroprotection, Part I: Immunosuppressants, Neurologic Disorders, and Neuroprotection, Ed: Borlongan & Sanberg, Humana Press Inc., Totowa, NJ, pp.3-32 Kiryu et al., In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal G.T Ischemia Reperfusion Injury, Poster Presentation 1247-B128 **EXAMINER** DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.

Include a copy of this form with next communication to applicant.

SUBSTITUTE (MODIFIED)	FORM	PTO-14	4 9				.S. DEPARTM PATENT AND T			ATTY. PMAN	DOCKET NO 1/25	Ο.	SERIA 10/667	
							OSURE PLICANT			APPLI Gholai	CANT m Peyman			
(37 CFR 1.98	(b))	(Us	se s	evera	al she	ets if n	ecessary)	-			3 DATE mber 19, 200	3	GROU 1615	IP
							U.S. F	PATENT	DOCUMENTS					
EXAMINER INITIAL		PA	λΤΕ	NT N	IUMBI	ER.	ISSUE DATE		PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	H.A				\prod									
-	н.в				П									
	н.с													
	H.D													
	H.E				П					·				
	H.F													
	H.G													
	н.н													
	H.1		T											
-	H.J													
	н.к													
•				FC	REIG	N PAT	ENTS OR PU	BLISHED	FOREIGN PA	TENT A	PPLICATION	IS		
				MEN 1BEF		Р	UBLICATION DATE		COUNTRY OF		CLASS	SUBCL	ASS	TRANSLATION (YES/NO)
	H.L													
	Н.М													
	H.N													
	H.O													
	Н.Р													
	H.Q													
				0	THER	DOC	UMENTS (Incli	uding Aut	hor, Title, Date	, Place o	of Publication)		
	H.R	Lai et 41(10)				nosup	pression prolo	ngs survi	val of RPE xen	ografts la	abeled by reti	roviral gei	ne transi	f <u>er,</u> IOVS (9/2000),
	H.S	Lallen Biopha	and	l et a aceu	I., <u>Cy</u> d tics, 4	lospor 5 (200	rine A delivery 3), pp. 307-318	to the eye	e: A pharmace	utical cha	allenge, Euro	pean Jou	rnal of P	harmaceutics and
	Н.Т	Lipner 19ff	, <u>Dr</u>	у Еу	e 101:	Devel	oping etiologie	s and trea	atrments fort hi	s widesp	oread syndron	me, EyeW	/orld, Fe	bruary 1999, pp.
EXAMINER									DATE CONS	IDERED				
							r not in conform n to applicant.	nance. D	raw line throug	h citatio	n only if not i	n conform	ance <u>ar</u>	not considered.

SUBSTITUTE (MODIFIED)	FORM	PTO-1	449	9	•					PARTN T AND						TTY.	DOCKE 25	ET NO	Э.	SERI/ 10/66			_
									OSUF								CANT n Peym	an					
(37 CFR 1.98	(b))	(l	Jse	se\	/era	ıl sh	eets	if ne	ecess	ary)							DATE	, 200	3	GROI 1615	JP		
										U.S.	PATE	ENT [DOCUM	ENTS									
EXAMINER INITIAL		F	PAT	ΓEN	T N	UMI	BER			SUE ATE			PATE	NTEE			CLA	ss	SUB	CLASS	II	FILING DATE APPROPRIATE	Ξ
	I.A																						
•	I.B																						
	I.C																						
	I.D																						
	I.E																						
	I.F	П												·									
	I.G	П										***	-							-			
	1.H	П																					
	1.1																						
•	l.J	\sqcap	┨																		1		
	I.K	TT																					
•					FO	REI	GN	PAT	ENTS	OR PL	JBLIS	HED	FORE	GN PA	TE	NT A	PPLICA	TION	IS				
		[CUN				PI		CATION			COUN				CLAS	s	SUBC	LASS	Т	RANSLATION (YES/NO)	
	I.L		٠,																				
	I.M																			-			
	I.N																						
	1.0																						
	I.P																						
	I.Q																						
					0	THE	R D	ocı	JMEN	ITS (inc	luding	g Aut	thor, Titl	e, Date	e, P	lace o	of Public	ation)	•			
	I.R	Lipp	er e	et al	., <u>R</u>	ecei	nt th	erap	eutic	advance	es in (derm	atology	JAMA	, V	ol. 28	3, No. 2	, Jan	uary 12,	2000, p	o, 17	5-177	
	I.S	Lope Visu	ez e	et al	, <u>Tra</u>	ansp (19	olant 89).	ed re	etinal 586-58	pigmen 38	t epitl	heliur	m modit	ies the	reti	inal d	egenera	tion i	n the RO	S, Inve	st. Op	hthalmology &	i.
	I.T	Lunc <u>rats</u> ,	et PN	al, NCS	Sub (20	retir	nal ti	rans _[[17]:9	planta 9942-	tion of 0	genet	ically	modifie	ed_hum	an (cell lii	nes atte	nuate	es loss o	f visual f	unctio	on in dystrophic	<u>c</u>
EXAMINER													DATE	CONS	IDE	RED							
EXAMINER: I	nitial if ci	tation form w	cor	nsid nex	ered	d, w	heth unic	er or	not in	n confor	rmano	ce. D	Praw line	throug	gh c	citatio	n only if	not i	n confor	mance <u>a</u>	<u>nd</u> no	ot considered.	

SUBSTITUTE (MODIFIED)	FORM	PTO-144	.9			S. DEPARTM			ATTY. PMAN	DOCKET NO /25	D .	SERIA 10/667	
						OSURE			APPLI Gholar	CANT n Peyman			
(37 CFR 1.98	(b))	(Us	e seve	eral sh	eets if n	ecessary)				S DATE nber 19, 200	3	GROU 1615	IP
						U.S. I	PATENT	DOCUMENTS					
EXAMINER INITIAL		PA	TENT	NUMI	BER	ISSUE DATE	-	PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	J.A												
	J.B												
	J.C												
	J.D			\Box									
	J.E												
	J.F												
	J.G												
J.H J.I													
J.H													
J.I J.J J.J J.J J.J J.J J.J J.J J.J J.J													
	J.K												
•			1	OREI	GN PAT	ENTS OR PU	BLISHED	FOREIGN PA	TENT A	PPLICATION	IS		
			CUM		P	PUBLICATION DATE	F	COUNTRY OF		CLASS	SUBCL	ASS	TRANSLATION (YES/NO)
	J.L										· · · · · · · · · · · · · · · · · · ·	<u>.</u>	
	J.M												
	J.N												
	J.O												
	J.P												
	J.Q												
				OTHE	R DOC	UMENTS (Incl	uding Aut	thor, Title, Date	, Place o	of Publication)		
	J.R	Martin Uveore	DF et	al., <u>Sy</u> The J	nergisti ournal o	c Effect of Rap of Immunology	amycin a , 1995, 1	nd Cyclosporin 54:922-927	A in the	Treatment o	of Experim	nental Au	utoimmune
	J.S					of deoxyspergu 92), 36(3):415		ne developmen	t of diabe	etes in diabet	es-prone	BB rats,	Scandinavian
	J.T	Passos pp.140		<u>Ocula</u>	r Toxici	ty of Intravitrea	al Tacrolir	nus, phthalmic	Surgery	and Lasers,	March/Ap	oril 2002,	, Vol. 33, No. 2,
EXAMINER								DATE CONS	IDERED	1			
						r not in conform n to applicant.		Oraw line throug	h citatio	n only if not i	n conform	nance <u>ar</u>	nd not considered.

SUBSTITUTE (MODIFIED)	FORM F	PTO-144	49				.S. DEPARTM ATENT AND T			ATTY. PMAN	DOCKET NO 25	Ο.	SERIA 10/667	
							OSURE LICANT			APPLI Gholar	CANT n Peyman			
(37 CFR 1.98	(b))	(Us	e se	vera	l shee	ts if n	ecessary)				DATE nber 19, 200	3	GROU 1615	P
			•				U.S. F	PATENT	DOCUMENTS					
EXAMINER INITIAL		PA	TEN	IT N	UMBE	:R	ISSUE DATE		PATENTEE	•	CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	K.A													
•	к.в													
	K.C													
	K.D													
	K.E													
	K.F													
	K.G													
	к.н													
	K.I													
•	K.J													
	K.K													
•				FO	REIG	N PAT	ENTS OR PU	BLISHED	FOREIGN PA	TENT A	PPLICATION	18		
			DCU NUM			Р	UBLICATION DATE	F	COUNTRY OF		CLASS	SUBCL	ASS	TRANSLATION (YES/NO)
	K.L													
	K.M													
	K.N													
	K.O		`											
	K.P											-		
	K.Q													
				0	THER	DOC	UMENTS (Incl	uding Aut	hor, Title, Date	e, Place o	of Publication	1)		
	K.R	PCT,	Inter	natio	nal Se	earch	Report, PCT/2	004/0240	54, mailed 07/	27/04, 7	pg.			
	K.S	PCT,	Inter	natio	nal S	earch	Report, PCT/U	S03/283	15, mailed 06/1	5/04, 6 p	pages			
	К.Т	Peym 449	an et	t al, j	Keratii	tis (No	ninfectious), P	rinciples	and Practice o	f Ophtha	lmology, W.E	3. Saunde	ers Com	pany, 1980, pp.446-
EXAMINER			·	·					DATE CONS	IDERED				
EXAMINER: Include a cop	Initial if ci	tation o	onsid h ne:	derec	d, whe	ther o	r not in conform n to applicant.	nance. D	Oraw line throug	gh citatio	n only if not i	in conform	nance <u>ar</u>	nd not considered.

SUBSTITUTE (MODIFIED)	FORM F	·TO-	144	9									COMME!			ATTY. PMAN		CKET	NO		SERI/ 10/66			
									OSUF ICAN							APPLI Gholar			ı					
(37 CFR 1.98((b))		(Use	e se	vera	ıl sh	eets	if ne	cessa	ary)						FILING Septer			003		GROI 1615			
										U.S.	PATI	ENT	DOCUME	ENTS	;									
EXAMINER INITIAL			PA ⁻	TEN	IT N	UMI	BER			SUE ATE			PATEN	TEE				CLASS	;	SUBC	LASS		FILING D	
	L.A																							
	L.B																							
	L.C																							
	L.D																							
	L.E																							_
	L.F																							
	L.G																							
	L.H											,												
	L.I																							
-	L.J																							
	L.K															,						\perp		
•					FO	REI	GN	PAT	ENTS	OR PL	JBLIS	SHED	FOREIG	SN PA	ΑT	ENT A	PPL	ICATI	ONS	s				
					MEN BER			Pl		CATION	7	F	COUNT			Ξ	C	_ASS		SUBCL	ASS		TRANSLA (YES/N	
	L.L																							
	L.M																					L		
	L.N																		╧			$oldsymbol{\perp}$		
	L.O																		1			┸		
	L.P																		\perp			oppi		
	L.Q																							
					0	ТНЕ	ER C	OCL	JMEN	ITS (Ind	cludin	g Au	thor, Title	, Date	e,	Place	of P	ublicat	ion)	١				
	L.R		ymà /06/0		Ocula	ar S	oluti	ons,	U.S. <i>i</i>	Applica	ition F	Public	ation No	. 2005	5/0	06399	7, pi	ublishe	ed 0	3/24/05,	Serial	No.	10/752,12	4, filed
	L.S	Pe	yma	n e	t al.,	Intr	avitr	eal S	urger	y: Princ	ciples	and	Practice,	2nd l	Ec	dition, 1	1994	, Aple	ton	& Lange	, CT, p	p. 4	43-452	
	L.Ţ	Pe 20	yma 01, (in et Cha	t al., pter	<u>Imp</u> 45,	plant	ation 521-5	of a :	sustain	ed-re	lease	ganciclo	vir im	npl	lant, Vi	treo	etinal	Sur	gical Te	chnique	es, N	Martin Dun	itz Ltd.,
EXAMINER													DATE	CONS	SIC	DEREC)							

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.

Sheet	13 (N	A)	of	15
		_		

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF PATENT AND TRADEM											ATTY. DOCKET NO. PMAN/25				SERIAL NO. 10/667,161				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT														APPLICANT Gholam Peyman					
(Use several sheets if necessary) (37 CFR 1.98(b))													FILING DATE September 19, 2003				GROUP 1615		
<u> </u>		Ť		•				*		U.S. P/	ATENT	росим	ENTS						
EXAMINER INITIAL		PATENT NUMBER							ISSUE R DATE				PATENTEE			CLASS		LASS	FILING DATE IF APPROPRIATE
	M.A																		
•	M.B													-					
	м.с																		
	M.D																		
	M.E																		
	M.F																		
	M.G																		
	м.н																		
	M.I																		
•	M.J																		
<u>-</u>	M.K																		
•					FC	RE	IGN	PAT	ENTS C	R PUB	LISHED	FOREIG	N PA	TENT A	PPLICA	ΓΙΟΝ	S		
		DOCUMENT NUMBER						PUBLICATION DATE				COUNTRY OR PATENT OFFICE		CLASS	3	SUBCL	ASS	TRANSLATION (YES/NO)	
	M.L																		
	M.M																		
	M.N									•									
	M.O																		
	M.P				•														
	M.Q																		
					0	ТНІ	ER C	ocu	JMENTS	S (Includ	ding Au	thor, Title	, Date	, Place	of Publica	ation)		
	M.R	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03											/05, Serial No.						
	M.S	Pey	mai	n et	al.,	<u>Intr</u>	avitr	eal c	irug ther	apy, Ja	panese	Journal o	of Oph	thalmolo	ogy (1989	9, 33	(4):392-4	04	
	M.T	Pey 10/	ma 289,	n, <u>Tı</u> 772	reat	me ed 1	nt of	Ocu //02	lar Disea	ase, U.S	S. Appli	cation Pu	blicati	on No. 2	2004/009	2435	, publishe	ed 05/13	/04, Serial No.
EXAMINER									DATE CONSIDERED										
EXAMINER: I											ance. [Draw line	throug	h citatio	n only if	not ir	n conform	ance <u>ar</u>	d not considered.

`												I			Sheet	14 (N)	of 15	
SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTME PATENT AND TR												ATTY. PMAN	DOCKET N 1/25	0.	SERIAL NO. 10/667,161			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT												APPLI Ghola	CANT m Peyman					
(Use several sheets if necessary) (37 CFR 1.98(b))									y)				G DATE mber 19, 200	3	GROUP 1615			
_									U.S. PA	ATENT DO	CUMENTS							
EXAMINER INITIAL	ΓEΝ	IT N	UME	BER	ISS DA		Р	ATENTEE	CLASS		SUBCLASS		FILING DATE IF APPROPRIATE					
	N.A																	
	N.B																	
	N.C																	
•	N.D											,						
	N.E																	
	N.F																	
	N.G																	
	N.H																	
	N.I																	
•	N.J																	
	N.K											 		<u> </u>				
-					FO	REI	GN PA	TENTS (OR PUBI	LISHED FO	OREIGN PA	TENT A	PPLICATION	NS				
		DOCUMENT P NUMBER					1	PUBLICA DAT			COUNTRY OR PATENT OFFICE				SUBCLASS		TRANSLATION (YES/NO)	
	N.L																	
	N.M																	
	N.N																	
	N.O																	
	N.P									<u> </u>								
	N.Q																	
					0	THE	R DOC	UMENT	S (Includ	ding Author	r, Title, Date	, Place	of Publication	1)				
	N.R		yman 19/0:		cula	r Sc	lutions	, U.S. Ar	plication	n Publicatio	on No. 2005	/006399	6, published	03/24/05,	Serial N	o. 10/667	,161, filed	

N.R Peyman, Ocular Solutions, U.S. Application Publication No. 2005/0063996, published 03/24/05, Serial No. 10/667,161, filed 09/19/03

N.S Revill et al., Genetically Engineered Analogs of Ascomycin for Nerve Regeneration, Journal of Pharmacology and Experimental Therapeutics, Vol. 302:1278-1285 (2002)

N.T Shen et al, Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina, Archives of Ophthalmology (7/2001), 119(7):1033-1043

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF PATENT AND TRADEM														SERIAL NO. 10/667,161		
							OSURE LICANT			APPLICANT Gholam Peyman						
(Use several sheets if necessary) (37 CFR 1.98(b))												DATE nber 19, 200	3	GROUP 1615		
								U.S.	PATENT	DOCUMENTS						
EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE		PATENTEE	CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
	O.A															
	O.B															
	O.C															
	O.D															
	O.E								:							
	O.F															
	O.G															
	O.H															
	0.1															
•	O.J															
	O.K															
4					FOI	REIGI	N PAT	ENTS OR PL	JBLISHEE	FOREIGN PA	TENT A	PPLICATION	IS			
		DOCUMENT NUMBER					Р	UBLICATION DATE		COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS		TRANSLATION (YES/NO)	
	O.L															
	O.M															
	O.N															
	0.0															
	0.P															
	0.Q															
			`		01	HER	DOC	UMENTS (inc	luding Au	thor, Title, Date	e, Place	of Publication)			
	O.R	Stosic-Grujicic et al, <u>Leflunomide protects mice from multiple low dose streptozotocin (MLD-SA)-induced insulitis and diabetes</u> , Clinical & Experimental Immunology (1999), 117(1):44-50											l insulitis and			
	o.s	Ueno publi	o, <u>U</u> she	lse c	of M 7/10	acroli	de Co Serial	mpounds for No. 10/354,08	the Treatr	nent of Dry Eye	<u>e,</u> U.S. P	atent Applica	tion Publi	cation 2	0030130301,	
	O.T	Wak	ele	e-Ly	nch	. <u>Inte</u>	feron	may offer firs	t drug the	rapy for diabeti	c retinop	athy, Diabete	es Care (1	992), 15	5(2):300-301	
EXAMINER										DATE CONSIDERED						
								r not in confor n to applicant		Draw line through	gh citatio	n only if not i	n conform	nance <u>ar</u>	nd not considered.	